Lenzing Biocel Paskov made a net profit of CZK 1,111 mil in 2019, down 21.6% compared to the previous year. Historically, between 2007 and 2019, the company's net profit reached a high of CZK 1,621 mil in 2017 and a low of CZK -99.0 mil in 2012.
The result implies a return on equity of 17.7% and a return on invested capital of 19.9% in 2019. That is compared to an average of 24.4% and 22.4% over the last five years.
The company has been operating with average EBITDA margin of 37.8% in the last 5 years and an average net margin of 24.0%.
Since 2014, the firm's net profit increased by 93.1% or an average of 14.1% a year.
You can see all the company’s data at Lenzing Biocel Paskov profile, or you can download a report on the company in the report section.
Helgi Library 
